The problem with "normal" vitamin D levels
When your blood test comes back with a vitamin D (25-hydroxyvitamin D) level of 32 ng/mL, most labs will flag it as "normal" or "sufficient." You get a checkmark. Your doctor says you're fine. And biochemically, you might not be.
The threshold of 30 ng/mL was established by the Institute of Medicine (IOM, now the National Academy of Medicine) in 2011, based primarily on the level needed to prevent rickets and severe bone disease[1]. It was never intended to define an optimal level for overall health. The Endocrine Society, in its clinical practice guidelines, explicitly recommends a minimum of 30 ng/mL but prefers 40-60 ng/mL for adequate health outcomes[2].
The difference between 32 and 50 ng/mL is not trivial. Research across multiple disciplines — bone metabolism, immune function, cardiovascular health, mental health, and cancer biology — suggests that benefits continue to accrue well above the 30 ng/mL "sufficient" threshold[3].
What the research says: 40-60 ng/mL
The most comprehensive analysis of the dose-response relationship between vitamin D levels and health outcomes was conducted by researchers including Robert Heaney, Bruce Hollis, and Michael Holick — the leading vitamin D scientists of the past three decades. Their work consistently points to 40-60 ng/mL (100-150 nmol/L) as the range where health benefits are maximized[3][4].
Bone health
Vitamin D is essential for calcium absorption. At levels below 30 ng/mL, calcium absorption is significantly impaired, leading to secondary hyperparathyroidism (the body pulls calcium from bones to maintain blood levels). PTH levels stabilize around 40 ng/mL in most studies, suggesting that this is the threshold at which calcium metabolism is fully optimized[5]. Fracture risk reduction in meta-analyses of supplementation trials is most consistent at achieved levels above 40 ng/mL.
Immune function
Vitamin D receptors are expressed on virtually every cell of the immune system. Vitamin D modulates both innate and adaptive immune responses — it enhances antimicrobial peptide production (cathelicidin), promotes anti-inflammatory cytokine profiles, and supports regulatory T-cell function[6].
Observational data consistently shows that individuals with vitamin D levels below 20 ng/mL have higher rates of upper respiratory infections, and supplementation trials have shown protective effects, particularly in people who are deficient at baseline. A 2017 individual-participant meta-analysis of 25 RCTs covering over 11,000 participants found that vitamin D supplementation reduced the risk of acute respiratory infection by 12% overall, and by 42% in participants with baseline levels below 25 nmol/L (10 ng/mL)[7].
Cardiovascular health
Low vitamin D is associated with increased cardiovascular risk in observational studies — higher rates of hypertension, heart failure, and cardiovascular mortality[8]. The relationship appears U-shaped, with the lowest risk around 40-50 ng/mL. The VITAL trial (25,871 participants, 5 years) found that vitamin D supplementation at 2,000 IU/day did not significantly reduce major cardiovascular events in the overall population, but participants who were deficient at baseline showed more pronounced benefits[9].
Mood and mental health
Vitamin D receptors are expressed throughout the brain, including regions involved in mood regulation. Meta-analyses of RCTs have shown modest but statistically significant antidepressant effects of vitamin D supplementation, particularly in individuals with clinical depression and low baseline vitamin D levels[10]. The effect size is small to moderate — vitamin D supplementation is not a substitute for established treatments, but it appears to be a meaningful adjunct.
Populations at higher risk of deficiency
Certain populations are disproportionately likely to have low vitamin D and may require higher supplemental doses to reach optimal levels:
- People with darker skin: Melanin reduces UVB-mediated vitamin D synthesis. Studies consistently show lower 25(OH)D levels in Black and South Asian populations at the same latitude[11].
- People living at high latitudes (>37th parallel): From approximately October through March in northern latitudes (including most of Europe, Canada, and the northern US), UVB radiation is insufficient to produce meaningful vitamin D regardless of sun exposure.
- Overweight and obese individuals: Vitamin D is fat-soluble and sequestered in adipose tissue, reducing its bioavailability. Obese individuals typically require 2-3x the supplemental dose to achieve the same blood levels as lean individuals[12].
- Older adults: The skin's capacity to synthesize vitamin D decreases with age. A 70-year-old produces approximately 25% as much vitamin D from the same sun exposure as a 20-year-old.
- People who use sunscreen consistently or cover most of their skin: SPF 30 reduces vitamin D synthesis by approximately 97%.
- People with malabsorption conditions: Celiac disease, Crohn's disease, and other GI conditions impair vitamin D absorption.
D3 vs D2: the evidence is clear
Vitamin D3 (cholecalciferol) is the form produced by human skin and is found in animal-derived foods (fatty fish, egg yolks, liver). Vitamin D2 (ergocalciferol) is plant-derived and historically used in prescription formulations. A head-to-head comparison published in the Journal of Clinical Endocrinology and Metabolism found that D3 is approximately 87% more potent at raising and maintaining 25(OH)D levels compared to D2 at equivalent doses[13].
The practical implication: always choose D3. Most over-the-counter supplements use D3 (cholecalciferol). If your doctor prescribes D2 (ergocalciferol), ask about D3 as an alternative.
The K2 cofactor
Vitamin D increases intestinal calcium absorption. Vitamin K2 (particularly the MK-7 form) activates two critical proteins: osteocalcin (which deposits calcium into bone) and matrix Gla protein (which prevents calcium from depositing in arteries and soft tissues)[14]. Without adequate K2, the increased calcium absorption from vitamin D supplementation could theoretically contribute to arterial calcification rather than bone building.
While definitive large-scale RCT evidence for the D3+K2 combination is still emerging, the mechanistic rationale is strong, the risk of K2 supplementation is negligible (no known toxicity), and many vitamin D researchers recommend concurrent K2, particularly at supplemental D3 doses above 2,000 IU/day. A common protocol is 100-200 mcg of MK-7 daily alongside D3.
Practical supplementation guide
| Current level | Suggested starting dose (D3) | Retest |
|---|---|---|
| < 20 ng/mL (deficient) | 5,000-10,000 IU/day for 8-12 weeks, then reduce | 8-12 weeks |
| 20-30 ng/mL (insufficient) | 4,000-5,000 IU/day | 8-12 weeks |
| 30-40 ng/mL (suboptimal) | 2,000-4,000 IU/day | 12 weeks |
| 40-60 ng/mL (optimal) | 1,000-2,000 IU/day (maintenance) | 6-12 months |
| > 60 ng/mL | Reduce or hold supplementation | 8-12 weeks |
Important absorption note: Vitamin D is fat-soluble. Take it with a meal that contains fat — even a small amount of butter, olive oil, or avocado significantly improves absorption. A study found that taking vitamin D with the largest meal of the day (typically containing the most fat) increased absorption by approximately 50% compared to taking it on an empty stomach.
Testing frequency
- Baseline: Before starting supplementation. This is your reference point.
- 8-12 weeks after starting or changing dose: Vitamin D has a half-life of approximately 2-3 weeks. It takes 8-12 weeks for blood levels to reach a new steady state after a dose change.
- Once stable (40-60 ng/mL): Test once or twice a year. Late winter (February-March) captures your annual low, and late summer (August-September) captures your annual high. This confirms your supplementation dose compensates for seasonal variation.